Regenerative medicine may help people living with diabetes by supporting the body’s natural repair processes, but it is not a cure, and anyone who tells you otherwise is overselling it. While regenerative medicine has not yet reliably restored normal blood sugar control or eliminated the need for diabetes management, it may offer supportive benefits for certain aspects of the disease.
At New Life Regenerative Medical Group in Virginia Beach, VA, diabetes is one of the conditions patients ask about most often. This article explains what regenerative medicine is, how it relates to diabetes care, what mesenchymal stem cell therapy can and cannot do, and where research is heading.
Regenerative medicine is built around a simple idea: instead of only managing symptoms, use the body’s own biological tools to repair, replace, or support damaged tissue.
Traditional medicine is very good at replacing what the body no longer makes. If your pancreas stops producing enough insulin, you inject insulin. That works, and it saves lives – but it does not address why the tissue stopped working in the first place.
Regenerative medicine takes a different angle, using cells, growth factors, and signaling molecules to influence the internal environment: reducing inflammation, improving blood flow to struggling tissue, and encouraging repair processes that slow with age, injury, or chronic disease.
“Diabetes” describes two fairly different problems:
Type 1 diabetes is autoimmune. The immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. Once enough beta cells are gone, lifelong insulin replacement becomes necessary.
Type 2 diabetes is primarily insulin resistance. The pancreas produces insulin, sometimes a great deal of it, but muscle, liver, and fat tissue stop responding properly. Over years, beta cells become exhausted and decline. Chronic low-grade inflammation drives and worsens this resistance.
Both forms involve immune dysregulation and inflammation – not just a hormone shortage. MSCs are known for two properties that map directly onto those problems: they modulate immune activity, and they reduce inflammatory signaling.
That is the basis for regenerative therapy in diabetes:
Protect remaining beta cells – quiet the autoimmune attack and inflammation threatening surviving cells.
Improve insulin sensitivity – reduce systemic inflammation so tissues respond better to available insulin.
Promote regeneration – support the microvascular, nerve, and tissue health that suffers in long-standing diabetes.
This same logic is why regenerative approaches are studied across other immune-driven conditions the clinic addresses, including rheumatoid arthritis, lupus, inflammatory bowel disease, and other autoimmune conditions. The common thread is an immune system that has lost its balance.
Mesenchymal stem cells are the workhorses of clinical regenerative medicine. Found in bone marrow, fat tissue, and umbilical cord tissue, they have been studied in thousands of trials across dozens of conditions. They are not embryonic stem cells.
Mechanisms researchers focus on in diabetes:
Immune modulation. MSCs shift immune cell behavior away from aggressive, inflammatory patterns toward regulatory, tolerant ones – relevant in type 1, especially for people recently diagnosed with residual beta cell function.
Reduced systemic inflammation. Lowering the inflammatory tone in fat and liver tissue is thought to improve how tissues respond to insulin in type 2.
Vascular support and angiogenesis. MSCs release factors that encourage small blood vessel formation and health, influencing wound healing, nerve function, and tissue oxygenation.
Neuroprotective signaling. Growth factors released by MSCs support nerve tissue – a focus of research into diabetic peripheral neuropathy’s burning, numbness, and pain.
Trophic support and beta cell protection. Rather than becoming new insulin-producing cells, MSCs “feed” and protect the ones you still have by reducing surrounding stress and inflammation.
Notice that most of these are supportive mechanisms. MSCs act as conductors of a healing orchestra.
The “secretome” is everything a stem cell secretes: growth factors, cytokines, messenger RNA, and tiny membrane packets called exosomes that carry instructions between cells. If the MSC is the factory, the secretome is the package of goods it ships out.
Potential advantages include:
Consistency. Secretome preparations can be characterized and standardized more predictably than living cell populations.
No living cells to reject. Signaling molecules do not carry the same immune considerations as whole cells.
Easier handling and storage. Living cells are fragile; molecular products are more stable.
Flexible delivery. Signals can be delivered systemically or targeted to a specific area, such as a region affected by neuropathy.
The tradeoff: signaling molecules do not stick around producing new signals the way living cells can – living cells act as sustained “drugstores.” Some protocols use cells, some use secretome products, and some combine both depending on the goal.
Autologous means the cells come from your own body – typically bone marrow or fat tissue. Immune compatibility is not a concern. But research consistently shows that cells taken from people with long-standing metabolic disease, chronic inflammation, or advanced age are fewer and less biologically active. The disease process that damaged your pancreas also affects your stem cell population. Harvesting also requires an additional procedure.
Allogeneic means the cells come from a screened donor source, most often umbilical cord tissue ethically donated after healthy, full-term births.
Our practice primarily utilizes allogeneic MSCs derived from umbilical cord tissue, for several reasons:
Potency. The cells are young, plentiful, robust, and highly active, with a powerful secretome.
Availability. Readily available, with no harvesting procedure – a simpler treatment day for the patient.
Immune-privileged. Umbilical cord MSCs express low levels of the surface markers that trigger rejection, so they are generally well tolerated without matching or immune-suppressing drugs.
Quality control. Reputable sources screen donors thoroughly for infectious disease, test each batch, and process cells in sterile lab conditions. Reported effects are usually mild and short-lived.
A few practical considerations for people with diabetes:
Blood sugar can fluctuate in the days surrounding any treatment – keep monitoring as usual.
Significant kidney involvement, cardiovascular disease, or a history of blood clots must be on the table during evaluation.
Never adjust insulin or diabetes medications based on how you feel after treatment. Those changes belong to your prescribing physician.
Not everyone is a candidate. A thorough screening process exists to identify that before anything else happens.
No. There is no cell therapy currently available that reliably restores normal, medication-free blood sugar regulation, and patients will still monitor blood sugar and work with their physician.
“Is it safe?” The allogeneic MSCs used at our practice come from umbilical cords donated after healthy, full-term births, rigorously screened for infectious disease and processed in a sterile lab.
“How is treatment administered?” Typically a simple intravenous (IV) infusion performed in our clinic as an outpatient procedure, with no significant downtime. The cells travel through the bloodstream to sites of inflammation and injury.
“Will I be able to stop my insulin or medications?” Plan on continuing everything your physician has prescribed. Regenerative therapy is complementary – any medication change is your prescribing doctor’s decision, based on your actual numbers over time.
“How soon would I notice anything?” Regenerative processes are gradual. Changes in inflammation-related symptoms, comfort, and energy – when they occur – typically develop over weeks to months, not days. It’s a marathon, not a sprint, and follow-up monitoring is part of our process.
“Is this experimental?” Regenerative therapy for diabetes is an emerging field. That is why an honest evaluation matters more than a sales pitch, and why realistic expectations are set before anything begins.
While not a cure, regenerative medicine may offer supportive benefits for some people with diabetes, particularly in managing inflammation, immune response, and tissue health. An individualized evaluation is essential to determine if it is appropriate for your situation. The goal is not to replace proven diabetes care, but to explore whether regenerative approaches may complement it as research continues to evolve.
About the Author
Dr. Robert Chandler
August 17, 2026
